When: Confirmed close above $164.20 on volume >4M with MACD expanding

Then: Add 25-33% with stop at breakout level

Hold current position intact for now; reduce by only 25% (not 50%) when price retests the $158 to $161 zone; set invalidation at 50 SMA close below $154.79 with volume; re-evaluate adding back if price breaks above $165.79 on volume.

• Net debt of $11.6 billion is manageable given $2.6B trailing nine-month FCF ($3.5B annualized) yielding approximately 9x interest coverage on $387M interest expense
• TTM EPS of $4.57 is distorted by $300-350M annual restructuring charges; normalized forward earnings closer to $6.50 with 12-15% organic growth, not 59%
• Q3 FY2026 revenue growth accelerated to 7% YoY from 3.7% in Q1; Q3 EPS hit multi-quarter high at $1.28; operating margins expanded 370bps since FY2022
• October 6th-7th upper Bollinger tag represents healthy uptrend, not distribution—volume lacked capitulation characteristics
• Current entry at $163.50 is chasing price given verified close of $162.33 and declining closes at $161.40 and $159.22
• Proposed stop at $165.79 ($2.29, less than 1 ATR of $3.91) sits in active supply zone and will get tagged on routine probes; conservative stop should be $169-$171 (1.5-2x ATR)
• Full 50% trim should be executed in $159-$161 zone, not $163.50-$165.24 resistance zone, to reduce exposure while tape cooperates
• Both institutional and retail channels returned zero mentions of EMR in past week indicating benign sentiment, not active distribution

→ vs aggressive: Distribution thesis unsupported by volume data—no capitulation characteristics on October 6th-7th declining sessions; stacked moving averages, expanding MACD, VWMA confirmation, and RSI at 63.9 indicate healthy uptrend, not supply overwhelming demand

→ vs neutral: HOLD recommendation is too passive—failing to size down modestly with predefined invalidation levels means accepting macro drag without optimizing risk-adjusted return; should reduce exposure incrementally rather than freeze in place

Trim 30% of position in two tranches: 15% at retest of 161.50-163.00 zone, 15% on either breakout above 165.24 with volume confirmation or failure at 10 EMA (~157.70); widen stop to 168.00; hard exit if price closes below 154.79 (50 SMA) on daily with volume

• Distribution thesis lacks evidence: zero institutional headlines, zero retail chatter, zero analyst actions; two-day pullback from 165.24 to 159.22 could be routine 2-3% cool-down after 10% rally in twelve sessions
• Net debt doubled YoY but FCF coverage of interest expense is approximately 9x at current run rates; stress scenario shows 4x-plus coverage, consistent with investment-grade leverage
• Forward EPS implied growth of 59% (4.57 to 7.27) is distorted by restructuring charges; normalized growth drops to mid-teens, consistent with peer industrial automation compounders
• Q3 FY24 revenue growth accelerated to 7%, EPS hit multi-quarter high at 1.28, operating margins expanded 370 basis points since FY22
• 10 EMA at 157.72 is first technical line of defense; price is within 1.5% of it after rejecting upper Bollinger Band; two consecutive declining closes broke short-term momentum
• Stop at 165.79 with 3.91 ATR from entry at 163.50 gives less than 1 ATR of room; proposed alternative of 169-171 is too wide at 2-2.5 ATR; middle ground of 168.00 provides 1.2 ATR breathing room
• 10Y at 2002 highs creates structural multiple compression risk for capex-levered names; prediction market pricing 96% probability of zero Fed cuts in 2026
• Q4 earnings catalyst in early November is binary event; sentiment data shows zero institutional headlines and zero retail chatter, suggesting light positioning and outsized reaction potential on results
• Hard invalidation at 154.79 (50 SMA) closes remaining position; full exit if price closes below 143.97 (200 SMA)
• Conservative analyst's tactical recommendation to sell into weakness in confirmed uptrend is logical inconsistency with bullish thesis; trimming should occur into strength, not weakness

→ vs aggressive: Distribution thesis lacks microstructure evidence: no volume confirmation, no widening spreads, no block prints; zero institutional signal cuts against the thesis; calling two-day Bollinger rejection a 'smoking gun' ignores alternate interpretation of routine cool-down after 10% rally

→ vs aggressive: Net debt doubling overstated as margin crisis; 9x FCF interest coverage and 4x-plus stress scenario is investment-grade leverage, not a margin destroyer; structural headwind yes, but different risk profile

→ vs aggressive: Forward EPS growth distorted by depressed TTM base; 59% implied growth normalizes to mid-teens consistent with peers; anchoring bear case to structurally depressed base year is methodologically questionable

→ vs conservative: Dismissal of Bollinger rejection as healthy cool-down ignores two consecutive declining closes breaking momentum; trends die at lower band after failing at upper band, and we are mid-sequence; calls for uncertainty not complacency

→ vs conservative: Tactical recommendation to trim into 158-161 zone after price has already declined contradicts bullish thesis; selling into weakness in confirmed uptrend is same error just criticized in aggressive analyst

→ vs conservative: Proposed stop at 169-171 is too wide at 2-2.5 ATR; changes risk-reward calculus materially